Ligand Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	251.23	167.13	131.31	196.25	241.54	163.56
Revenue Growth (YoY)	64.83%	27.28%	-33.09%	-18.75%	47.68%	35.98%
Cost of Revenue	96.49	32.5	35.05	88.91	94.28	70.92
Gross Profit	154.74	134.63	96.27	107.34	147.26	92.64
Selling, General & Admin	93.03	78.65	52.79	70.06	46.79	39.31
Amortization of Goodwill & Intangibles	32.87	32.96	33.65	34.24	34.22	11.64
Other Operating Expenses	-	-	-	-	-	0.6
Operating Expenses	125.9	111.61	86.44	104.3	81.01	51.55
Operating Income	28.85	23.02	9.82	3.04	66.25	41.09
Interest Expense	-3.81	-3.04	-0.66	-1.8	-19.62	-27.42
Interest & Investment Income	9.2	8.06	7.71	2.05	0.89	8.08
Earnings From Equity Investments	-7.04	-12.8	-	-	-	-
Other Non Operating Income (Expenses)	-17.29	-31.37	-0.78	-0.01	-0.35	2.53
EBT Excluding Unusual Items	9.9	-16.13	16.1	3.28	47.17	24.28
Merger & Restructuring Charges	-	-	-	-	-	-20.7
Gain (Loss) on Sale of Investments	57.16	49.22	46.37	28.54	-5.26	-16.93
Gain (Loss) on Sale of Assets	-	-	2.12	-	-	17.11
Asset Writedown	-4.08	-30.57	-0.92	-	-	-
Other Unusual Items	-	-	-	4.19	30.3	-2.47
Pretax Income	62.98	2.52	63.66	36.01	72.21	1.29
Income Tax Expense	14.4	6.55	9.84	41.23	-4.15	-5.31
Earnings From Continuing Operations	48.58	-4.03	53.82	-5.22	76.35	6.6
Earnings From Discontinued Operations	-	-	-1.67	-28.14	-19.22	-9.58
Net Income to Company	48.58	-4.03	52.15	-33.36	57.14	-2.99
Net Income	48.58	-4.03	52.15	-33.36	57.14	-2.99
Net Income to Common	48.58	-4.03	52.15	-33.36	57.14	-2.99
Net Income Growth	7.38%	-	-	-	-	-
Shares Outstanding (Basic)	19	18	17	17	17	16
Shares Outstanding (Diluted)	19	18	18	17	17	17
Shares Change (YoY)	6.20%	3.00%	5.27%	-2.19%	2.50%	-14.84%
EPS (Basic)	2.52	-0.22	3.02	-1.98	3.44	-0.18
EPS (Diluted)	2.49	-0.22	2.94	-1.98	3.32	-0.18
EPS Growth	0.76%	-	-	-	-	-
Free Cash Flow	30.76	95.23	46.06	125.5	70.04	50.13
Free Cash Flow Per Share	1.58	5.21	2.59	7.44	4.06	2.98
Gross Margin	61.59%	80.55%	73.31%	54.70%	60.97%	56.64%
Operating Margin	11.48%	13.77%	7.48%	1.55%	27.43%	25.12%
Profit Margin	19.34%	-2.41%	39.72%	-17.00%	23.66%	-1.82%
Free Cash Flow Margin	12.24%	56.98%	35.07%	63.95%	29.00%	30.65%
EBITDA	63.03	58.26	46.34	41.35	117.2	69.05
EBITDA Margin	25.09%	34.86%	35.29%	21.07%	48.52%	42.22%
D&A For EBITDA	34.19	35.24	36.52	38.32	50.95	27.97
EBIT	28.85	23.02	9.82	3.04	66.25	41.09
EBIT Margin	11.48%	13.77%	7.48%	1.55%	27.43%	25.12%
Effective Tax Rate	22.86%	260.13%	15.46%	114.49%	-	-
Revenue as Reported	251.23	167.13	131.31	196.25	241.54	163.56

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q